The 2026 HRT Boxed Warning Change, Explained
In November 2025 the FDA began removing boxed warning language about heart disease, breast cancer and dementia from menopause hormone therapy labels, and approved the first six updated labels on February 12, 2026. The endometrial cancer warning stays on estrogen-alone products.
Yes, partly. On November 10, 2025, the FDA announced it would remove boxed warning language about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels, and on February 12, 2026 it approved updated labeling for the first six products. The boxed warning about endometrial cancer remains on systemic estrogen-alone products, and the change does not mean hormone therapy is risk free for everyone.
Key takeaways
- A boxed warning is the FDA's most prominent label warning; menopause hormone products carried one for more than 20 years.
- The FDA is removing the boxed language on heart disease, breast cancer and probable dementia, product by product.
- The endometrial cancer boxed warning stays on systemic estrogen-alone products.
- Updated labels recommend starting systemic therapy within 10 years of menopause onset or before age 60.
- The change applies to FDA-approved products; compounded hormones have no FDA-approved label.
What changed and when
According to the HHS fact sheet published on November 10, 2025, the FDA initiated removal of boxed warning language on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products. The agency asked manufacturers to submit label changes.
On February 12, 2026, the FDA announced that it had approved the first labeling changes for six products spanning the main categories of hormone therapy. Other products follow as companies submit and the agency reviews their changes, so for a while some labels will be updated and others not.
What stayed the same
The boxed warning about endometrial cancer remains on systemic estrogen-alone products. If you have a uterus, estrogen without a progestogen can thicken the uterine lining and raise the risk of endometrial cancer, which is why a progestogen is usually added. Labels still describe risks such as blood clots and stroke in the warnings section, just not in a box.
The updated labeling also recommends starting systemic hormone therapy within 10 years of menopause onset or before age 60, consistent with evidence that the balance of benefit and risk is more favorable earlier.
Why the FDA made the change
The original boxed warnings were added after the early Women's Health Initiative results in 2002. Those trials enrolled women whose average age was in the early 60s and used specific older hormone products. Later analyses showed that age and time since menopause strongly influence risk. The Menopause Society's 2022 position statement had already concluded that for healthy women under 60 or within 10 years of menopause, benefits for bothersome symptoms generally outweigh risks.
What The Menopause Society said
The Menopause Society commented on the announcement the same day. It supported removing the boxed warning from low-dose vaginal estrogen, which acts mainly where it is applied, and it emphasized that systemic estrogen still carries risks for some women, greater when started later in life. In practice, the label change reduces fear but does not replace an individual risk review.
Does it apply to compounded hormones?
Not directly. The FDA changed the labeling of FDA-approved products. The FDA's compounding guidance explains that compounded drugs are not FDA-approved, so they have no FDA-approved label to change. The evidence about estrogen and progesterone still applies however a product is made, so your licensed provider runs the same safety review either way.
What it means for you
If you avoided hormone therapy because of the warning, it may be worth a fresh conversation, especially if you are under 60 or within 10 years of your last period and your symptoms affect sleep, work or relationships. If you have a history of breast or uterine cancer, blood clots, stroke, heart attack, liver disease or unexplained vaginal bleeding, hormone therapy is still generally not recommended, and non-hormone options deserve a look.
Frequently asked questions
Does removing the boxed warning mean hormone therapy is safe now?
It means the FDA no longer considers boxed warnings on those specific risks appropriate for these products. Risks such as blood clots and stroke remain in the label, and your age, timing and history still decide what is right for you.
Is it too late to start hormone therapy at 60 or 65?
It is not automatically ruled out, but timing matters. Updated labeling recommends starting systemic therapy before 60 or within 10 years of menopause, and risks are greater when therapy starts later. Low-dose vaginal estrogen is a different situation.
Why does the endometrial cancer warning remain?
Because estrogen without a progestogen raises the risk of endometrial cancer in women with a uterus. Adding a progestogen protects the lining, which is why most women with a uterus take both.
Will my current product's label change?
If it is an FDA-approved product, its manufacturer is expected to update the label, and the FDA reviews changes product by product. Your pharmacist can tell you which version you have.
Talk to a licensed provider
The label change is a good reason to revisit a decision, not to skip the safety review. Start an online menopause visit and a licensed provider will go through the updated evidence with you. This article is educational and does not determine eligibility for any treatment.
Sources
- HHS fact sheet, FDA initiates removal of boxed warnings from menopausal hormone therapy products (Nov 10, 2025)
- FDA, FDA approves labeling changes to menopausal hormone therapy products (Feb 12, 2026)
- The Menopause Society comments on the FDA announcement on hormone therapy (Nov 10, 2025)
- FDA, Compounding and the FDA: Questions and Answers
- The 2022 hormone therapy position statement of The North American Menopause Society, Menopause (2022)
This article is educational and is not medical advice. Golden Glow content is written to be accurate and is reviewed against the sources above. Rx programs require an online visit with a licensed provider. Results vary.